# 2026-08435: FDA Greenlights Ozempic Generics: Safe or Just Bureaucratic Assurance?

2026-08435, Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-30, effective 2026-04-30; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-08435
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08435
- Title: Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 23276
- Published: 2026-04-30
- Effective: 2026-04-30
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Greenlights Ozempic Generics: Safe or Just Bureaucratic Assurance?

## Summary

The FDA has decided that OZEMPIC (semaglutide) 2 mg/1.5 mL wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep applying to sell their versions, and the FDA will keep approving them if they meet the rules. Patients and pharmacies can feel confident that OZEMPIC remains a safe and effective option.

## Abstract

The Food and Drug Administration (FDA or Agency) has determined that OZEMPIC (semaglutide) solution, 2 milligrams (mg)/1.5 milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

## Effects PRIA read

- Generics May Continue Seeking Approval: benefit, medium. The FDA determined that OZEMPIC (semaglutide) 2 mg/1.5 mL was not withdrawn from sale for reasons of safety or effectiveness, so generic applicants may continue to submit abbreviated new drug applications (ANDAs) that refer to this product and the FDA will continue to approve such ANDAs if they mee…
- Patients and Pharmacies Reassured on OZEMPIC: benefit, low. If you take or dispense OZEMPIC (semaglutide) 2 mg/1.5 mL, the FDA has determined it was not withdrawn for reasons of safety or effectiveness, and the product will remain listed in the Orange Book's Discontinued Drug Product List while ANDAs referring to it may be approved if they meet requirements.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-08435 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/30/2026-08435/determination-that-ozempic-semaglutide-solution-2-milligrams-per-15-milliliters-was-not-withdrawn)
- [2026-08435 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-30/pdf/2026-08435.pdf)

## Related
- [Previous: 2026-08434, GCM Grosvenor Private Equity Capital Opportunities Fund and GCM Grosvenor Wealt…](https://policyrisk.com/federal-register/2026-08434)
- [Next: 2026-08436, Agency Information Collection Activities; Submission to the Office of Managemen…](https://policyrisk.com/federal-register/2026-08436)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08435 (as of 2026-06-08).
